EXEL

Exelixis Inc

• Simply Wall St·2d ago

  Exelixis Returned 46% On A Case The Market Still Has Not Settled

• NASDAQ·4d ago

  Biotech Stocks At 52-Week Highs - PGEN, EXEL, TWST, HNGE, PBYI

• Seeking Alpha·09/24 20:32

  Merck Welireg, Eisai Lenvima combo approved for kidney cancer

• Simply Wall St·09/23 18:32

  How Investors Are Reacting To Exelixis (EXEL) FDA Review Extension

• NASDAQ·09/23 13:50

  Here's Why Exelixis (EXEL) is a Strong Momentum Stock

• NASDAQ·09/22 15:04

  Noteworthy ETF Inflows: XMHQ, MEDP, MANH, EXEL

• NASDAQ·09/22 12:53

  Alpha Teknova (TKNO) Moves 7.1% Higher: Will This Strength Last?

• Simply Wall St·09/17 22:28

  Can Exelixis (EXEL) Stay Cheap After A 185% Five Year Run?

• NASDAQ·09/17 15:03

  Exelixis Eyes Oncology Deals, Readies Zanzalintinib Launch as Cabozantinib Tops $3B

• Simply Wall St·09/16 16:22

  Does Extended FDA Review Change The Bull Case For Exelixis (EXEL)?

• NASDAQ·09/15 11:03

  Exelixis Eyes Zanza Launch as CABOMETYX Growth Faces NET Ramp Hurdle

• Simply Wall St·09/15 09:24

  Exelixis (EXEL) Looks Fully Valued After FDA Review Delay

• TipRanks·09/14 15:10

  Analysts Offer Insights on NA Companies: Exelixis (EXEL) and Resolution Minerals Ltd. Sponsored ADR (RML)

• TipRanks·09/14 14:45

  Exelixis Rated Hold as Zanzalintinib CRC Outlook Remains Mixed; $54 Price Target Reaffirmed

• Seeking Alpha·09/14 14:00

  Exelixis: Why The 3-Month Delay Is More Negative Than It May Seem (Downgrade)